CagriSema: Phase 3 Results, Dosing, Side Effects, and What to Expect in 2026

CagriSema is an investigational once-weekly injectable weight-loss medication from Novo Nordisk that combines two active peptides, semaglutide and cagrilintide, in a single dose. In Phase 3 clinical trials, it helped adults without diabetes lose up to 22.7% of their body weight over 68 weeks, and adults with type 2 diabetes lose up to 15.7%. It is not FDA approved yet, but a regulatory submission is expected in early 2026, which puts a potential U.S. launch in late 2026. If you have been following GLP-1 weight-loss news, or if you have hit a plateau on Wegovy or Zepbound and are wondering what comes next, this guide breaks down everything the current data shows.

What Is CagriSema?

CagriSema is a fixed-dose combination of two peptides delivered as one weekly subcutaneous shot. The semaglutide component is the same molecule found in Wegovy, Ozempic and Rybelsus. The cagrilintide component is a long-acting amylin analog developed by Novo Nordisk. Amylin is a natural hormone released by the pancreas alongside insulin, and it plays a big role in appetite and stomach emptying that GLP-1 drugs on their own do not target. Because CagriSema pairs two different hormone pathways in one injection, researchers describe it as a dual agonist rather than a pure GLP-1. Novo Nordisk originally planned a dual-chamber pen, but recent studies confirmed the drug works well in a single-chamber FlexTouch pen, the same device Ozempic uses.

CagriSema Mechanism of Action: How the Semaglutide and Cagrilintide Combination Works

The two peptides in CagriSema work on different receptors, and that is exactly why the combination pushes weight loss further than either drug alone. Semaglutide activates GLP-1 receptors, which slows gastric emptying, reduces liver glucose output, and signals the brain’s appetite centers to feel full sooner. Cagrilintide mimics amylin, which also slows how fast the stomach empties, boosts satiety after a meal, and helps flatten post-meal blood sugar spikes. Stacked together, they hit hunger, portion size and glucose control from two directions at once. That is the same “multi-mechanism” logic behind tirzepatide, though the pathways are different.

CagriSema Phase 3 Results 2025: Novo Nordisk REDEFINE Trials

Novo Nordisk ran two large Phase 3 studies, REDEFINE 1 and REDEFINE 2, both 68 weeks long. The findings were presented at the 85th Scientific Sessions of the American Diabetes Association in June 2025 and published in the New England Journal of Medicine. REDEFINE 1 enrolled 3,400 adults with obesity but no diabetes. Average weight loss with CagriSema hit 20.4%, and 22.7% when adjusted for full treatment adherence. About 40.4% of participants lost 25% or more of their starting body weight. For comparison, semaglutide alone produced 14.9% weight loss, cagrilintide alone produced 11.5%, and placebo delivered just 3%. REDEFINE 2 enrolled 1,200 adults with type 2 diabetes. CagriSema drove an average 13.7% weight loss versus 3.4% for placebo, rising to 15.7% with full adherence. HbA1c reduction and glucose control tracked with what you would expect from a semaglutide-based therapy, and the safety profile matched the broader GLP-1 class.

CagriSema Weight Loss Results at a Glance

• Adults without diabetes: 20.4% average, 22.7% with adherence
• Adults with type 2 diabetes: 13.7% average, 15.7% with adherence
• Placebo: 3% (non-diabetic) and 3.4% (diabetic)
• 40.4% of REDEFINE 1 participants reached 25%+ weight loss

Novo Nordisk had internally aimed for a 25% weight-loss target, and REDEFINE 1 fell slightly short. One likely reason: only about half of participants reached the highest dose in the trial window. A follow-up study starting in 2025 is testing a slower, more patient-friendly titration schedule.

CagriSema Dosing and Dosage Chart

The full CagriSema dosing schedule has not been finalized because the drug is still investigational, but the Phase 3 trials give us a clear picture of the starting dose and titration pattern. Both semaglutide and cagrilintide start low and step up together over roughly 16 weeks.

Week	Semaglutide	Cagrilintide
1 to 4	0.25 mg	0.25 mg
5 to 8	0.5 mg	0.5 mg
9 to 12	1.0 mg	1.0 mg
13 to 16	1.7 mg	1.7 mg
17+	2.4 mg	2.4 mg

The maintenance dose used in REDEFINE 1 and 2 was 2.4 mg of each peptide, delivered once weekly. This gradual step-up helps the gut adjust and cuts down on nausea. For weight loss specifically, staying on the 2.4 mg maintenance dose long-term is what drives the biggest results. Higher-dose formulations like a CagriSema 20 mg version are not part of the current label pathway, so anything sold online at that strength today is unregulated.

CagriSema Side Effects

Side effects reported in the REDEFINE program lined up with the GLP-1 class overall. Most were mild to moderate and tapered off as patients adjusted to each dose step.

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Loss of appetite

Serious events were rare. As with other GLP-1 medications, CagriSema is not recommended for patients with a personal or family history of medullary thyroid cancer, MEN2 syndrome, severe gastroparesis, or during pregnancy and breastfeeding.

CagriSema vs Tirzepatide, Zepbound, Semaglutide and Retatrutide

CagriSema vs Tirzepatide (and Zepbound)

Tirzepatide is a single molecule that hits both GLP-1 and GIP receptors, and it is sold as Zepbound for weight loss and Mounjaro for diabetes. In SURMOUNT trials, tirzepatide delivered up to 21% weight loss in adults without diabetes over 72 weeks. CagriSema showed 22.7% at 68 weeks, but Novo Nordisk is running a direct head-to-head trial (NCT06131437) that will settle the comparison in a way indirect data cannot.

CagriSema vs Semaglutide (Wegovy)

This one is cleaner because both drugs share a molecule. In REDEFINE 1, semaglutide alone drove 14.9% weight loss, while CagriSema drove 20.4%. Adding cagrilintide clearly moves the needle for patients who plateau on semaglutide.

CagriSema vs Retatrutide

Retatrutide is Eli Lilly’s investigational triple-agonist (GLP-1, GIP, and glucagon). Phase 2 data showed weight loss around 24% at 48 weeks, but retatrutide is still earlier in development. Direct comparisons are not available yet, and Phase 3 retatrutide results will land after CagriSema has already filed for approval.

CagriSema FDA Approval Status 2026

CagriSema is not yet FDA approved. Novo Nordisk has confirmed plans to submit a regulatory application for obesity in early 2026, based on the REDEFINE 1 and 2 data. A standard FDA review typically takes 10 to 12 months, so a U.S. launch could realistically happen in late 2026, though delays are always possible. The company is also running REDEFINE 3, a cardiovascular outcomes trial, and additional trials for long-term safety and dose optimization. Those studies will support future indications like heart risk reduction, similar to Wegovy’s cardiovascular label.

CagriSema Price and Where to Buy

Official pricing has not been announced because CagriSema is not on the market. Analyst estimates suggest it will likely land in the same monthly cost range as Wegovy and Zepbound, which run around $1,000 to $1,350 per month before insurance or manufacturer savings programs. Anything advertised as “CagriSema for sale” or “CagriSema 20 mg online” today is unregulated and should be avoided. The only safe path is to wait for FDA approval or ask your bariatric team about currently approved options.

CagriSema News: Latest Updates

The biggest recent update was the June 2025 ADA presentation of the full REDEFINE 1 and 2 datasets in The New England Journal of Medicine. Novo Nordisk has also announced a new trial in 2025 focused on optimizing dose escalation to help more patients reach the top dose. Beyond that, the head-to-head study against tirzepatide and the REDEFINE 3 cardiovascular trial are both ongoing and expected to deliver readouts through 2026 and 2027.

Where CagriSema Fits Alongside Bariatric Surgery

Medications like CagriSema are a real step forward, but they are not a replacement for surgery in every case. Patients with a BMI over 40, or over 35 with obesity-related conditions like type 2 diabetes or sleep apnea, still see the most durable long-term results from procedures like gastric sleeve, gastric bypass, duodenal switch and SADI-S. For patients who prefer a non-surgical route or need a bridge before surgery, our medical weight management program uses currently approved GLP-1 therapies alongside nutrition and lifestyle support. And for patients who have regained weight after previous surgery, revision weight loss surgery is often the right conversation to have. Our board-certified team sees patients across Arlington, Richardson, Dallas, and Texarkana.